🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,146 results for “Yung” Clear

  1. Sertraline combined with Lactobacillus crispatus

    The First People's Hospital of Lianyungang

    Major Depressive Disorder (MDD)

    phase 2 other active

    1 trial

  2. Sintilimab

    The First People's Hospital of Lianyungang

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  3. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  4. Sintilimab

    The First People's Hospital of Lianyungang

    EBV-Positive DLBCL, Nos

    phase 2 small molecule active

    1 trial

  5. Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Sintilimab

    The First People's Hospital of Lianyungang

    Carcinoma

    phase 2 mab active

    1 trial

  8. Sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  9. Sintilimab Combined with Platinum-containing Chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Sintilimab with Interleukin-2+CAPOX

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  11. Sintilimab,nab-paclitaxel and tegio

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  12. Sodium stibogluconate

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  13. Sonodynamic therapy(SDT)

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other terminated

    1 trial

  14. Stem Cell Educator

    The First People's Hospital of Lianyungang

    Alopecia Areata

    phase 2 other active

    1 trial

  15. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  16. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  17. TACE with adebrelimab and bevacizumab

    The First People's Hospital of Lianyungang

    Adebrelimab

    phase 2 small molecule active

    1 trial

  18. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  19. Telitacicept

    The First People's Hospital of Lianyungang

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  20. Temozolomide

    The First People's Hospital of Lianyungang

    Cytokine-Induced Killer Cells

    phase 2 small molecule active

    1 trial

  21. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  22. Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

    The First People's Hospital of Lianyungang

    Hematological Malignancy

    phase 2 small molecule active

    1 trial

  23. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  24. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources